{
  "name": "Drug formulation evidence: FDA and EMA crosswalk",
  "description": "Original comparison of formulation evidence discussed in FDA Q8(R2) and the EMA excipient dossier guideline. Cells identify complementary development and documentation topics, with section references. This is a reading aid, not a universal testing specification.",
  "page": "https://casrai.org/guides/drug-formulation",
  "publisher": "CASRAI",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "dateModified": "2026-11-17T01:57:38Z",
  "temporalCoverage": null,
  "spatialCoverage": null,
  "columns": [
    {
      "name": "Evidence area",
      "unit": "",
      "description": ""
    },
    {
      "name": "FDA Q8(R2) discussion",
      "unit": "",
      "description": ""
    },
    {
      "name": "EMA excipient guideline discussion",
      "unit": "",
      "description": ""
    }
  ],
  "rows": [
    {
      "Evidence area": "Component role",
      "FDA Q8(R2) discussion": "Parent 2.1.2: relate excipient choice, concentration and relevant characteristics to its function.",
      "EMA excipient guideline discussion": "4.1: list excipient name, quantity, function and reference standard."
    },
    {
      "Evidence area": "Material grade and properties",
      "FDA Q8(R2) discussion": "Parent 2.1.2: discuss characteristics influencing performance or manufacturability.",
      "EMA excipient guideline discussion": "4.1–4.2: identify commercial grade when needed to describe functional properties and explain its choice."
    },
    {
      "Evidence area": "Compatibility",
      "FDA Q8(R2) discussion": "Parent 2.1.1–2.1.2: evaluate drug substance–excipient compatibility and relevant excipient interactions.",
      "EMA excipient guideline discussion": "4.2: establish compatibility with active substances and, where relevant, other excipients."
    },
    {
      "Evidence area": "Function-related controls",
      "FDA Q8(R2) discussion": "Parent 2.1.2: demonstrate intended excipient functionality throughout product shelf life.",
      "EMA excipient guideline discussion": "4.3–4.4: additional functionality-related tests may be necessary, including relevant viscosity, emulsification or dispersion properties."
    },
    {
      "Evidence area": "Novel excipient support",
      "FDA Q8(R2) discussion": "Parent 2.1.2: cross-reference supporting excipient safety information where appropriate in 3.2.P.4.6.",
      "EMA excipient guideline discussion": "4.6: provide manufacture, characterisation and controls with cross-references to supporting safety data."
    },
    {
      "Evidence area": "Antimicrobial preservation",
      "FDA Q8(R2) discussion": "Parent 2.5: distinguish routine chemical content testing from effectiveness demonstrated during development.",
      "EMA excipient guideline discussion": "4.8: monitor preservative levels during stability; establish simulated in-use effectiveness for relevant multidose non-solid products."
    }
  ],
  "sources": [
    {
      "title": "FDA: Q8(R2) Pharmaceutical Development",
      "url": "https://www.fda.gov/media/71535/download",
      "accessed": "2026-11-17"
    },
    {
      "title": "EMA: Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product, Revision 2",
      "url": "https://www.ema.europa.eu/en/scientific-guidelines/excipients-dossier-application-marketing-authorisation-medicinal-product",
      "accessed": "2026-11-17"
    }
  ]
}